Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer (Adenocarcinoma)
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Acerand Therapeutics (Hong Kong) Limited
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Diego, Moores Cancer Center · La Jolla, CA
Florida · 1
- Moffitt Cancer Center, Tampa · Tampa, FL
Maryland · 1
- University of Maryland, Greenebaum Comprehensive Cancer Center · Baltimore, MD
Massachusetts · 1
- Harvard Medical School-Massachusetts General Hospital · Boston, MA
Minnesota · 1
- M Health Fairview Clinics and Surgery Center · Minneapolis, MN
South Carolina · 1
- Carolina Urologic Research Center · Myrtle Beach, SC
Washington · 1
- Fred Hutchinson Cancer Research Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.